Skip to main content
Top
Published in: BMC Gastroenterology 1/2011

Open Access 01-12-2011 | Research article

Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model

Authors: Rainer Noth, Julia Lange-Grumfeld, Eckhard Stüber, Marie-Luise Kruse, Mark Ellrichmann, Robert Häsler, Jochen Hampe, Burkhard Bewig, Philip Rosenstiel, Stefan Schreiber, Alexander Arlt

Published in: BMC Gastroenterology | Issue 1/2011

Login to get access

Abstract

Background

Hematopoietic stem cell transplantation is increasingly performed for hematologic diseases. As a major side effect, acute graft versus host disease (GvHD) with serious gastrointestinal symptoms including diarrhea, gastrointestinal bleeding and high mortality can be observed. Because surveillance and biopsies of human gastrointestinal GvHD are difficult to perform, rare information of the alterations of the gastrointestinal barrier exists resulting in a need for systematic animal models.

Methods

To investigate the effects of GvHD on the intestinal barrier of the small intestine we utilized an established acute semi allogenic GvHD in C57BL/6 and B6D2F1 mice.

Results

By assessing the differential uptake of lactulose and mannitol in the jejunum, we observed an increased paracellular permeability as a likely mechanism for disturbed intestinal barrier function. Electron microscopy, immunohistochemistry and PCR analysis indicated profound changes of the tight-junction complex, characterized by downregulation of the tight junction protein occludin without any changes in ZO-1. Furthermore TNF-α expression was significantly upregulated.

Conclusions

This analysis in a murine model of GvHD of the small intestine demonstrates serious impairment of intestinal barrier function in the jejunum, with an increased permeability and morphological changes through downregulation and localization shift of the tight junction protein occludin.
Appendix
Available only for authorised users
Literature
2.
go back to reference Washington K, Jagasia M: Pathology of graft-versus-host disease in the gastrointestinal tract. Human pathology. 2009, 40 (7): 909-917. 10.1016/j.humpath.2009.04.001.CrossRefPubMed Washington K, Jagasia M: Pathology of graft-versus-host disease in the gastrointestinal tract. Human pathology. 2009, 40 (7): 909-917. 10.1016/j.humpath.2009.04.001.CrossRefPubMed
3.
go back to reference Takatsuka H, Iwasaki T, Okamoto T, Kakishita E: Intestinal graft-versus-host disease: mechanisms and management. Drugs. 2003, 63 (1): 1-15. 10.2165/00003495-200363010-00001.CrossRefPubMed Takatsuka H, Iwasaki T, Okamoto T, Kakishita E: Intestinal graft-versus-host disease: mechanisms and management. Drugs. 2003, 63 (1): 1-15. 10.2165/00003495-200363010-00001.CrossRefPubMed
4.
go back to reference Reddy P: Pathophysiology of acute graft-versus-host disease. Hematological oncology. 2003, 21 (4): 149-161. 10.1002/hon.716.CrossRefPubMed Reddy P: Pathophysiology of acute graft-versus-host disease. Hematological oncology. 2003, 21 (4): 149-161. 10.1002/hon.716.CrossRefPubMed
5.
go back to reference Morris ES, Hill GR: Advances in the understanding of acute graft-versus-host disease. British journal of haematology. 2007, 137 (1): 3-19.CrossRefPubMed Morris ES, Hill GR: Advances in the understanding of acute graft-versus-host disease. British journal of haematology. 2007, 137 (1): 3-19.CrossRefPubMed
6.
go back to reference Ross WA, Couriel D: Colonic graft-versus-host disease. Curr Opin Gastroenterol. 2005, 21 (1): 64-69.PubMed Ross WA, Couriel D: Colonic graft-versus-host disease. Curr Opin Gastroenterol. 2005, 21 (1): 64-69.PubMed
7.
go back to reference Guy-Grand D, Vassalli P: Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest. 1986, 77 (5): 1584-1595. 10.1172/JCI112474.CrossRefPubMedPubMedCentral Guy-Grand D, Vassalli P: Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest. 1986, 77 (5): 1584-1595. 10.1172/JCI112474.CrossRefPubMedPubMedCentral
8.
go back to reference Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.PubMed Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.PubMed
9.
go back to reference Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D: Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology. 1999, 116 (3): 593-601. 10.1016/S0016-5085(99)70181-2.CrossRefPubMed Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D: Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology. 1999, 116 (3): 593-601. 10.1016/S0016-5085(99)70181-2.CrossRefPubMed
10.
go back to reference Liu XC, Mei Q, Xu JM, Hu J: Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice. Acta pharmacologica Sinica. 2009, 30 (7): 987-993. 10.1038/aps.2009.77.CrossRefPubMedPubMedCentral Liu XC, Mei Q, Xu JM, Hu J: Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice. Acta pharmacologica Sinica. 2009, 30 (7): 987-993. 10.1038/aps.2009.77.CrossRefPubMedPubMedCentral
11.
go back to reference Li N, Gu L, Qu L, Gong J, Li Q, Zhu W, Li J: Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci. 2010, 40 (1): 1-8. 10.1016/j.ejps.2010.02.001.CrossRefPubMed Li N, Gu L, Qu L, Gong J, Li Q, Zhu W, Li J: Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci. 2010, 40 (1): 1-8. 10.1016/j.ejps.2010.02.001.CrossRefPubMed
12.
go back to reference Sasatomi K, Sakisaka S, Kawaguchi T, Hanada S, Taniguchi E, Koga H, Harada M, Sata M: Cholestasis in a rat model of graft-versus-host disease is accompanied by alteration of the expression and distribution of tight-junction-associated proteins. Int J Mol Med. 2005, 15 (3): 431-436.PubMed Sasatomi K, Sakisaka S, Kawaguchi T, Hanada S, Taniguchi E, Koga H, Harada M, Sata M: Cholestasis in a rat model of graft-versus-host disease is accompanied by alteration of the expression and distribution of tight-junction-associated proteins. Int J Mol Med. 2005, 15 (3): 431-436.PubMed
13.
go back to reference Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, Watson AJ: The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology. Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, Watson AJ: The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology.
14.
go back to reference Tang Y, Clayburgh DR, Mittal N, Goretsky T, Dirisina R, Zhang Z, Kron M, Ivancic D, Katzman RB, Grimm G, et al: Epithelial NF-kappaB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation. Am J Pathol. 176 (1): 158-167. Tang Y, Clayburgh DR, Mittal N, Goretsky T, Dirisina R, Zhang Z, Kron M, Ivancic D, Katzman RB, Grimm G, et al: Epithelial NF-kappaB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation. Am J Pathol. 176 (1): 158-167.
15.
go back to reference Chen J, Xiao L, Rao JN, Zou T, Liu L, Bellavance E, Gorospe M, Wang JY: JunD represses transcription and translation of the tight junction protein zona occludens-1 modulating intestinal epithelial barrier function. Mol Biol Cell. 2008, 19 (9): 3701-3712. 10.1091/mbc.E08-02-0175.CrossRefPubMedPubMedCentral Chen J, Xiao L, Rao JN, Zou T, Liu L, Bellavance E, Gorospe M, Wang JY: JunD represses transcription and translation of the tight junction protein zona occludens-1 modulating intestinal epithelial barrier function. Mol Biol Cell. 2008, 19 (9): 3701-3712. 10.1091/mbc.E08-02-0175.CrossRefPubMedPubMedCentral
16.
go back to reference Clayburgh DR, Musch MW, Leitges M, Fu YX, Turner JR: Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest. 2006, 116 (10): 2682-2694. 10.1172/JCI29218.CrossRefPubMedPubMedCentral Clayburgh DR, Musch MW, Leitges M, Fu YX, Turner JR: Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest. 2006, 116 (10): 2682-2694. 10.1172/JCI29218.CrossRefPubMedPubMedCentral
17.
go back to reference Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, Watterson DM, Clarke LL, Mrsny RJ, Turner JR: Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest. 2005, 115 (10): 2702-2715. 10.1172/JCI24970.CrossRefPubMedPubMedCentral Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, Watterson DM, Clarke LL, Mrsny RJ, Turner JR: Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest. 2005, 115 (10): 2702-2715. 10.1172/JCI24970.CrossRefPubMedPubMedCentral
18.
go back to reference Clayburgh DR, Shen L, Turner JR: A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004, 84 (3): 282-291. 10.1038/labinvest.3700050.CrossRefPubMed Clayburgh DR, Shen L, Turner JR: A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004, 84 (3): 282-291. 10.1038/labinvest.3700050.CrossRefPubMed
19.
go back to reference Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, Shalowitz D, Mittal N, Efthimiou P, Alnadjim Z, et al: T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest. 2002, 110 (11): 1739-1747.CrossRefPubMedPubMedCentral Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, Shalowitz D, Mittal N, Efthimiou P, Alnadjim Z, et al: T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest. 2002, 110 (11): 1739-1747.CrossRefPubMedPubMedCentral
20.
go back to reference Paris L, Tonutti L, Vannini C, Bazzoni G: Structural organization of the tight junctions. Biochim Biophys Acta. 2008, 1778 (3): 646-659. 10.1016/j.bbamem.2007.08.004.CrossRefPubMed Paris L, Tonutti L, Vannini C, Bazzoni G: Structural organization of the tight junctions. Biochim Biophys Acta. 2008, 1778 (3): 646-659. 10.1016/j.bbamem.2007.08.004.CrossRefPubMed
21.
go back to reference Laukoetter MG, Bruewer M, Nusrat A: Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006, 22 (2): 85-89. 10.1097/01.mog.0000203864.48255.4f.CrossRefPubMed Laukoetter MG, Bruewer M, Nusrat A: Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006, 22 (2): 85-89. 10.1097/01.mog.0000203864.48255.4f.CrossRefPubMed
22.
go back to reference Schulzke JD, Fromm M: Tight junctions: molecular structure meets function. Ann N Y Acad Sci. 2009, 1165: 1-6. 10.1111/j.1749-6632.2009.04925.x.CrossRefPubMed Schulzke JD, Fromm M: Tight junctions: molecular structure meets function. Ann N Y Acad Sci. 2009, 1165: 1-6. 10.1111/j.1749-6632.2009.04925.x.CrossRefPubMed
23.
go back to reference Shen L, Weber CR, Turner JR: The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol. 2008, 181 (4): 683-695. 10.1083/jcb.200711165.CrossRefPubMedPubMedCentral Shen L, Weber CR, Turner JR: The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol. 2008, 181 (4): 683-695. 10.1083/jcb.200711165.CrossRefPubMedPubMedCentral
24.
go back to reference Mankertz J, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M, Schulzke JD: Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci. 2000, 113 (Pt 11): 2085-2090.PubMed Mankertz J, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M, Schulzke JD: Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci. 2000, 113 (Pt 11): 2085-2090.PubMed
25.
go back to reference Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002, 97 (8): 2000-2004. 10.1111/j.1572-0241.2002.05914.x.CrossRefPubMed Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002, 97 (8): 2000-2004. 10.1111/j.1572-0241.2002.05914.x.CrossRefPubMed
26.
go back to reference Marano CW, Lewis SA, Garulacan LA, Soler AP, Mullin JM: Tumor necrosis factor-alpha increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol. 1998, 161 (3): 263-274. 10.1007/s002329900333.CrossRefPubMed Marano CW, Lewis SA, Garulacan LA, Soler AP, Mullin JM: Tumor necrosis factor-alpha increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol. 1998, 161 (3): 263-274. 10.1007/s002329900333.CrossRefPubMed
27.
go back to reference Hering NA, Schulzke JD: Therapeutic options to modulate barrier defects in inflammatory bowel disease. Digestive diseases (Basel, Switzerland). 2009, 27 (4): 450-454. 10.1159/000233283.CrossRef Hering NA, Schulzke JD: Therapeutic options to modulate barrier defects in inflammatory bowel disease. Digestive diseases (Basel, Switzerland). 2009, 27 (4): 450-454. 10.1159/000233283.CrossRef
28.
go back to reference Turner JR: Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol. 2006, 169 (6): 1901-1909. 10.2353/ajpath.2006.060681.CrossRefPubMedPubMedCentral Turner JR: Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol. 2006, 169 (6): 1901-1909. 10.2353/ajpath.2006.060681.CrossRefPubMedPubMedCentral
29.
go back to reference Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, et al: Nod2 regulates the host response towards microflora by modulating T cell function and epithelial permeability in mouse Peyer's patches. Gut. 59 (2): 207-217. Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, et al: Nod2 regulates the host response towards microflora by modulating T cell function and epithelial permeability in mouse Peyer's patches. Gut. 59 (2): 207-217.
30.
go back to reference Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL: LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. The Journal of clinical investigation. 2001, 107 (12): 1581-1589. 10.1172/JCI12156.CrossRefPubMedPubMedCentral Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL: LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. The Journal of clinical investigation. 2001, 107 (12): 1581-1589. 10.1172/JCI12156.CrossRefPubMedPubMedCentral
31.
go back to reference Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. 1992, 175 (2): 405-413. 10.1084/jem.175.2.405.CrossRefPubMed Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. 1992, 175 (2): 405-413. 10.1084/jem.175.2.405.CrossRefPubMed
32.
go back to reference Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL: Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999, 104 (4): 459-467. 10.1172/JCI6896.CrossRefPubMedPubMedCentral Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL: Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999, 104 (4): 459-467. 10.1172/JCI6896.CrossRefPubMedPubMedCentral
33.
go back to reference Mazzon E, Cuzzocrea S: Role of TNF-alpha in ileum tight junction alteration in mouse model of restraint stress. American journal of physiology. 2008, 294 (5): G1268-1280.PubMed Mazzon E, Cuzzocrea S: Role of TNF-alpha in ileum tight junction alteration in mouse model of restraint stress. American journal of physiology. 2008, 294 (5): G1268-1280.PubMed
34.
go back to reference Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E: Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. American journal of physiology. 2008, 294 (4): G938-947.PubMed Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E: Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. American journal of physiology. 2008, 294 (4): G938-947.PubMed
35.
go back to reference Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA: Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. The Journal of surgical research. 2007, 140 (1): 12-19. 10.1016/j.jss.2006.07.050.CrossRefPubMed Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA: Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. The Journal of surgical research. 2007, 140 (1): 12-19. 10.1016/j.jss.2006.07.050.CrossRefPubMed
36.
go back to reference Oshima T, Miwa H, Joh T: Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. American journal of physiology. 2008, 295 (3): C800-806. 10.1152/ajpcell.00157.2008.CrossRefPubMed Oshima T, Miwa H, Joh T: Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. American journal of physiology. 2008, 295 (3): C800-806. 10.1152/ajpcell.00157.2008.CrossRefPubMed
37.
go back to reference Meyer zum Buschenfelde D, Tauber R, Huber O: TFF3-peptide increases transepithelial resistance in epithelial cells by modulating claudin-1 and -2 expression. Peptides. 2006, 27 (12): 3383-3390. 10.1016/j.peptides.2006.08.020.CrossRefPubMed Meyer zum Buschenfelde D, Tauber R, Huber O: TFF3-peptide increases transepithelial resistance in epithelial cells by modulating claudin-1 and -2 expression. Peptides. 2006, 27 (12): 3383-3390. 10.1016/j.peptides.2006.08.020.CrossRefPubMed
Metadata
Title
Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model
Authors
Rainer Noth
Julia Lange-Grumfeld
Eckhard Stüber
Marie-Luise Kruse
Mark Ellrichmann
Robert Häsler
Jochen Hampe
Burkhard Bewig
Philip Rosenstiel
Stefan Schreiber
Alexander Arlt
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2011
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-11-109

Other articles of this Issue 1/2011

BMC Gastroenterology 1/2011 Go to the issue